VNVALUEVNVALUE
Updated weekly
Back to Dashboard
Consumer sector

CDP

Consumer
Công ty Cổ phần Dược phẩm Trung ương Codupha
Y tế/Dược phẩmCT
17.100
VND · Last close
Valuation Verdict
Overvalued
Very Low
-120%Fair Value+120%
Intrinsic Value
6.231
Current
17.100
Gap
-63.6%
ModelFCF DCF

Valuation Breakdown

CTY tếConsumer
Classified as consumer because ICB sector "Y tế" maps to the consumer group
ModelFCF-Based DCF
Value = Sum of [FCF / (1+WACC)^t] + Terminal Value / (1+WACC)^n

A classic Discounted Cash Flow model built on Free Cash Flow (FCF), the actual cash a business generates after all operating expenses and capital expenditures. Future FCF is projected for 10 years with gradually decaying growth, then discounted back to today's value using WACC. This is the gold standard of intrinsic valuation: it values the company based on what it can actually deliver to shareholders, independent of market sentiment.

Distressed Valuation
Negative Intrinsic Value
BVPS
12.463
x
Discount
50%
=
Floor Value
12.463

Valuation Track Record

Retroactive intrinsic value vs actual close price — CDP

Earnings Quality

Fiscal year 2025

36
Weak
Accrual Quality
79
Cash Conversion
0
Receivables
64
Margin Stability
1
Revenue Quality
22

Financial Forensics

Beneish M-Score · 2025

-2.01
Moderate
DSRI
1.195
GMI
1.114
AQI
0.882
SGI
1.024
DEPI
0.968
SGAI
0.885
TATA
0.052
LVGI
1.008

CDP exhibits several indicators of potential earnings manipulation, as evidenced by its Beneish M-Score of -2.0089, which is below the manipulation threshold of -1.78. Additionally, the company has a concerning Earnings Quality Score of 36.1/100, indicating significant issues with cash conversion and revenue recognition.

Red Flags
  • Beneish M-Score of -2.0089 indicates a high likelihood of earnings manipulation, significantly below the threshold of -1.78.
  • Earnings Quality Score of 36.1/100, particularly low cash conversion score of 0.0/100, raises concerns about the sustainability of reported earnings.
Positive Signals
  • DSRI of 1.1947 suggests that inventory levels are in line with sales growth, which may indicate operational stability.
  • Ownership concentration with 66.3% held by Tổng Công ty Dược Việt Nam could imply strong institutional backing, potentially leading to more stable governance.
Ownership Risk

The high concentration of ownership by institutional investors, particularly Tổng Công ty Dược Việt Nam, may mitigate some governance risks but also raises concerns about minority shareholder rights and potential conflicts of interest.

Recommendation

Investors should exercise caution and closely monitor CDP's financial disclosures and operational performance. It may be prudent to wait for improved earnings quality metrics and transparency before considering investment.

Generated by AI based on quantitative data. Not financial advice.

Quantitative Scores

F-Score
4/9
Neutral
Z-Score
1.53
Distress Zone
Sharpe
1.24
Excellent
Composite
38
Weak
Price Risk
Momentum
+31.7%
Volatility
69.8%
Max Drawdown
-17.8%

Key Ratios

Fiscal year 2025
8.49P/E
P/B1.32
P/S0.09
ROE15.9%
ROA1.6%
EPS1937.19
BVPS12462.92
Gross Margin6.6%
Net Margin1.1%
D/E9.60
Current Ratio1.03
Rev Growth3.1%
Profit Growth85.6%
EV/EBITDA17.73
Div Yield2.4%

Company Overview

Issued Shares
18.3M
Charter Capital
182.7B VND
Sector (ICB L2)
Y tế
Industry (ICB L3)
Dược phẩm
Sub-industry
Dược phẩm
Company Type
CT

// OWNERSHIP_NETWORK

> mapping common ownership for CDP — hover nodes for intel, click to navigate

Shareholders
Tổng Công ty Dược Việt Nam
Inst
66.3%
12.1 trieu
Công ty Cổ phần Chứng khoán DSC
Inst
14.9%
2.7 trieu
Công ty Cổ phần Quản lý Quỹ NTP
Inst
8.3%
1.5 trieu
Board & Management
Bùi Hữu Hiền
Tổng Giám đốc/Thành viên Hội đồng Quản trị
Trương Chí Thiện
Thành viên Ban kiểm soát
Đinh Thị Khởi
Phó Tổng Giám đốc/Thành viên Hội đồng Quản trị
Nguyễn Văn Tuất
Kế toán trưởng
Lê Văn Sơn
Chủ tịch Hội đồng Quản trị
Chu Thị Bích Hồng
Phụ trách Công bố thông tin/Thành viên Ban kiểm soát
Nguyễn Văn Khái
Thành viên Ban kiểm soát
Phạm Thứ Triệu
Thành viên Hội đồng Quản trị
Trần Anh Tuấn
Thành viên Hội đồng Quản trị
Computed 12/04/2026
Methodology & Disclosure

vnvalue is a methodology engine — not an advisor. Every number is the deterministic output of a published formula applied to public financial data. Nothing on this page constitutes investment, financial, legal, or tax advice, nor a recommendation to buy, sell, or hold any security.

All data, models, and outputs are provided AS IS without warranty of any kind. You are solely responsible for your investment decisions. Past performance and historical valuations are not indicative of future results.

By using vnvalue you accept the Terms of Service and Privacy Policy. Full disclaimer →